Suppliers and packagers for PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209008	ANDA	Better Living Brands LLC	21130-158-67	2 BLISTER PACK in 1 CARTON (21130-158-67) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2023-09-01
Aurobindo Pharma	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209008	ANDA	Aurohealth LLC	58602-804-67	2 BLISTER PACK in 1 CARTON (58602-804-67) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2017-06-09
Aurobindo Pharma	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209008	ANDA	Aurohealth LLC	58602-804-83	1 BLISTER PACK in 1 CARTON (58602-804-83) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2017-06-09
Aurobindo Pharma Ltd	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	218854	ANDA	WALGREEN CO.	0363-6611-10	1 BLISTER PACK in 1 CARTON (0363-6611-10) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2026-01-30
Aurobindo Pharma Ltd	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	218854	ANDA	Aurohealth LLC	58602-884-27	1 BLISTER PACK in 1 CARTON (58602-884-27) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2025-12-29
Aurobindo Pharma Ltd	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	218854	ANDA	Aurohealth LLC	58602-884-58	2 BLISTER PACK in 1 CARTON (58602-884-58) / 5 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2025-12-29
L Perrigo Co	PSEUDOEPHEDRINE HYDROCHLORIDE	pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	075153	ANDA	L. Perrigo Company	0113-0054-52	10 BLISTER PACK in 1 CARTON (0113-0054-52) / 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	1999-10-29

Pseudoephedrine Hydrochloride: Global Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for pseudoephedrine hydrochloride, a key precursor in the synthesis of methamphetamine and a widely used decongestant. It identifies key manufacturers, production capacities, regulatory frameworks, and emerging market dynamics that impact its availability and price for legitimate pharmaceutical use.

Who are the Primary Manufacturers of Pseudoephedrine Hydrochloride?

The production of pseudoephedrine hydrochloride is concentrated among a limited number of global manufacturers, primarily located in Asia. These companies hold significant market share due to their established infrastructure, economies of scale, and experience in navigating complex regulatory environments.

• Hubei Biocause Pharmaceutical Co., Ltd. (China): A dominant player, Hubei Biocause is consistently cited as one of the largest producers. The company has significant manufacturing capacity and a well-established distribution network, supplying both domestic and international markets [1].
• Shandong Xinhua Pharmaceutical Co., Ltd. (China): Another major Chinese producer, Shandong Xinhua also contributes substantially to the global supply. Its production scale and technical expertise are key factors in its market position [2].
• Anqiu Zhongbang Pharmaceutical Co., Ltd. (China): This company is a notable producer, contributing to the overall output of pseudoephedrine hydrochloride from China.
• Amneal Pharmaceuticals (United States): While not a primary raw material producer on the same scale as Asian counterparts, Amneal Pharmaceuticals has been involved in the formulation and packaging of pseudoephedrine-based products in the U.S. market, relying on imported Active Pharmaceutical Ingredient (API) [3].
• Other Manufacturers: Several smaller manufacturers exist in China and India, though their individual production volumes are less impactful on the global aggregate. These often supply niche markets or operate under contract for larger distributors.

Table 1: Estimated Pseudoephedrine Hydrochloride Manufacturing Capacity

Manufacturer	Country	Estimated Annual Capacity (Metric Tons)
Hubei Biocause Pharmaceutical Co., Ltd.	China	5,000 - 7,000
Shandong Xinhua Pharmaceutical Co., Ltd.	China	3,000 - 4,500
Anqiu Zhongbang Pharmaceutical Co., Ltd.	China	1,500 - 2,000
Various Smaller Producers (Asia)	China, India	2,000 - 3,000
Total Estimated Global Capacity		11,500 - 16,500

Note: Capacity figures are estimates based on industry reports and company disclosures, subject to fluctuation and market demand.

What are the Key Production Processes and Raw Materials?

The synthesis of pseudoephedrine hydrochloride typically begins with ephedrine or a precursor that can be readily converted to ephedrine. The industrial production is a multi-step chemical synthesis process.

• Starting Materials:

  • Ephedrine: This is the most direct precursor. It can be isolated from Ephedra plants or synthesized chemically.
  • Sassafras Oil (Safrole): Historically, safrole, a component of sassafras oil, was used to synthesize ephedrine. However, due to strict regulations on safrole due to its illicit use in methamphetamine production, its use as a direct precursor for legitimate pharmaceutical manufacturing is heavily controlled and limited.
  • Other Chemical Precursors: Various chemical synthesis routes exist that bypass the direct use of ephedrine or safrole, involving compounds like benzaldehyde or propiophenone, which are then converted through several reaction steps.

• Key Synthesis Steps (Simplified):

  1. Reaction: Chemical reactions involving the chosen precursor to form the pseudoephedrine base.
  2. Purification: Separation of the desired pseudoephedrine base from byproducts and impurities through methods like distillation and crystallization.
  3. Salt Formation: Reaction of the pseudoephedrine base with hydrochloric acid (HCl) to produce pseudoephedrine hydrochloride, a stable salt form suitable for pharmaceutical formulation.
  4. Drying and Packaging: The final product is dried and packaged for distribution.

Table 2: Primary Raw Material Sources and Considerations

Raw Material	Primary Source Region	Regulatory Oversight	Notes
Ephedrine	Synthetically produced	International Narcotics Control Board (INCB) controls	Production often occurs in countries with strong chemical manufacturing bases.
Benzaldehyde	Global chemical industry	Standard chemical industry regulations	Widely available, but strict tracking for precursors is increasing.
Propiophenone	Global chemical industry	Standard chemical industry regulations	Subject to scrutiny as a potential precursor.
Hydrochloric Acid	Global chemical industry	Standard chemical industry regulations	Widely available commodity chemical.
Sassafras Oil	Southeast Asia	Heavily regulated under UN conventions	Use for legitimate pharmaceutical precursor production is highly restricted.

What are the Regulatory Frameworks Governing Pseudoephedrine Hydrochloride?

The dual nature of pseudoephedrine hydrochloride as a legitimate medication and a controlled precursor necessitates stringent regulatory oversight globally. These regulations aim to prevent diversion to illicit drug manufacturing while ensuring access for patients.

• International Controls:

  • United Nations Conventions: Pseudoephedrine is listed under the UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. This mandates signatory countries to implement controls on its international trade [4].
  • International Narcotics Control Board (INCB): The INCB monitors the legitimate international trade in pseudoephedrine and ephedrine to prevent diversion. Manufacturers and traders must report international shipments, and import/export authorizations are often required [5].

• National Regulations (Examples):

  • United States:
    • Combat Methamphetamine Epidemic Act of 2005 (CMEA): This act placed restrictions on the retail sale of pseudoephedrine-based products, requiring them to be kept behind the counter and limiting purchase quantities [6].
    • Drug Enforcement Administration (DEA): The DEA classifies pseudoephedrine and ephedrine as List I chemicals, meaning their manufacture, distribution, and import/export are strictly regulated. Companies handling these chemicals must register with the DEA, maintain detailed records, and report suspicious transactions.
  • Canada:
    • Controlled Drugs and Substances Act: Pseudoephedrine is a controlled substance. Regulations govern its sale, possession, and manufacture, with similar behind-the-counter requirements for retail sales.
    • Health Canada: Oversees the licensing and regulation of manufacturers and distributors.
  • European Union:
    • Regulation (EC) No 273/2004: Classifies ephedrine and pseudoephedrine as Category 1 precursors, requiring strict licensing and reporting for trade within the EU and with third countries [7].
    • National Agencies: Member states implement these regulations through their respective health and drug enforcement agencies.
  • Australia:
    • Therapeutic Goods Administration (TGA): Regulates the importation and supply of pseudoephedrine. It is classified as a Schedule 4 (Prescription Only Medicine) or Schedule 3 (Pharmacist Only Medicine) substance depending on the formulation and dosage, with restrictions on over-the-counter sales.

Table 3: Key Regulatory Bodies and Oversight Mechanisms

Region/Country	Primary Regulatory Body	Key Legislation/Regulation	Oversight Mechanisms
Global	INCB	UN Convention Against Illicit Traffic (1988)	International trade monitoring, reporting requirements, import/export authorizations.
United States	DEA, FDA	Combat Methamphetamine Epidemic Act of 2005 (CMEA)	Behind-the-counter sales, purchase limits, List I chemical registration, record keeping.
Canada	Health Canada	Controlled Drugs and Substances Act	Behind-the-counter sales, licensing, strict import/export controls.
European Union	National Agencies (e.g., EMA)	Regulation (EC) No 273/2004	Licensing, reporting, Category 1 precursor controls.
Australia	TGA	Therapeutic Goods Act	Scheduling, prescription/pharmacist-only requirements, import controls.

What are the Market Dynamics and Pricing Factors?

The market for pseudoephedrine hydrochloride is influenced by a complex interplay of legitimate pharmaceutical demand, regulatory pressures, and the persistent threat of illicit diversion.

• Demand Drivers:

  • Over-the-Counter (OTC) Decongestants: The primary legitimate demand comes from its use in cold, flu, and allergy medications. Consumer demand for these products is seasonal and influenced by weather patterns and the prevalence of respiratory illnesses.
  • Prescription Medications: It is also a component in some prescription formulations for conditions like COPD or asthma, though this is a smaller segment of demand.
  • Geographic Variation: Demand varies by region, influenced by local prevalence of conditions, regulatory access to alternative decongestants, and cultural purchasing habits.

• Supply-Side Factors:

  • Manufacturing Concentration: The limited number of large-scale manufacturers, particularly in China, creates a degree of supply chain dependency. Any disruption at a major facility can have global ripple effects.
  • Regulatory Compliance Costs: Manufacturers face significant costs associated with meeting stringent regulatory requirements, including security measures, record-keeping, and reporting. These costs are often passed on to consumers.
  • Raw Material Availability and Cost: Fluctuations in the price and availability of key chemical precursors can impact production costs and ultimately the price of pseudoephedrine hydrochloride.
  • Enforcement Actions: Seizures of illicit drug labs and arrests of individuals involved in precursor diversion can lead to increased scrutiny and temporary disruptions in supply chains as authorities tighten controls.

• Pricing Trends:

  • Stable but Increasing: Over the past decade, the price of pseudoephedrine hydrochloride for legitimate pharmaceutical use has shown a generally stable to slightly increasing trend. This is attributed to rising compliance costs, increasing demand for legitimate products, and the inherent inefficiencies introduced by strict regulations.
  • Regional Price Differentials: Prices can vary significantly between regions due to import duties, local distribution costs, and differing national regulatory enforcement levels.
  • Impact of Illicit Market: While not directly priced, the illicit demand for pseudoephedrine as a methamphetamine precursor exerts indirect pressure. Law enforcement crackdowns on illicit operations can lead to heightened vigilance and regulatory hurdles for legitimate handlers, potentially increasing their operational costs.

Table 4: Key Factors Influencing Pseudoephedrine Hydrochloride Pricing

| Factor | Impact on Price | Notes | | :----------------{0} | :-------------- | :--------------------------------------------------------------------------------------------------------------------- | | Regulatory Compliance | Increases | Costs associated with security, tracking, reporting, and licensing. | | Raw Material Costs | Fluctuates | Dependent on global chemical commodity prices and availability of specific precursors. | | Legitimate Demand | Increases | Seasonal demand for OTC cold/flu/allergy products drives consistent baseline demand. | | Supply Chain Disruptions | Increases | Production issues, natural disasters, or geopolitical events affecting major manufacturing hubs. | | Enforcement Actions | Indirectly increases | Increased vigilance and administrative burden for legitimate handlers following crackdowns on illicit operations. | | Transportation Costs | Increases | Global shipping costs, especially for regulated chemicals, add to the landed cost. |

What are the Emerging Market Trends and Future Outlook?

The future supply chain for pseudoephedrine hydrochloride will likely be shaped by ongoing efforts to balance public health needs with the imperative to combat illicit drug manufacturing.

• Technological Advancements in Detection and Tracking:

  • DNA/Trace Tagging: Manufacturers may increasingly adopt technologies to tag batches of pseudoephedrine hydrochloride with unique identifiers, facilitating tracking and verification of legitimate use.
  • Blockchain Technology: Potential applications of blockchain for secure, transparent, and auditable tracking of precursor chemicals throughout the supply chain are being explored.

• Shifting Manufacturing Landscape:

  • Diversification Efforts: While China remains dominant, there is a gradual trend towards exploring manufacturing capabilities in other regions to mitigate single-source dependencies, though this is complex due to regulatory hurdles.
  • Increased Vertical Integration: Some pharmaceutical companies may explore greater vertical integration, potentially moving towards direct API synthesis or tighter control over precursor sourcing to ensure supply chain integrity.

• Regulatory Evolution:

  • Stricter International Cooperation: Increased collaboration between national regulatory bodies and international organizations like the INCB is anticipated to harmonize controls and improve information sharing regarding suspicious transactions.
  • Focus on Alternative Precursors: As controls on pseudoephedrine tighten, illicit manufacturers may seek alternative precursors, prompting regulatory bodies to expand their scope of monitoring.

• Development of Alternative Decongestants:

  • Phenylephrine: The increased regulatory restrictions on pseudoephedrine have led to its replacement by phenylephrine in some OTC products, particularly in the U.S. market. However, the efficacy of phenylephrine is a subject of ongoing debate and regulatory review, which could impact its long-term viability as a wholesale substitute.
  • Non-Pharmacological Solutions: Continued research into non-pharmacological approaches to managing nasal congestion could influence overall demand for pseudoephedrine-based medications.

Table 5: Emerging Trends and Their Potential Impact

Trend	Potential Impact on Pseudoephedrine Hydrochloride Supply Chain	Timeline
Enhanced Tracking Technologies	Improved supply chain integrity, reduced diversion risk, potential for increased compliance costs.	Medium Term
Geographic Manufacturing Diversification	Potentially more resilient supply, but requires significant investment and navigation of complex international regulations.	Long Term
Evolving Regulatory Frameworks	Continued tightening of controls, potential for greater international harmonization, increased administrative burdens.	Ongoing
Rise of Alternative Decongestants (e.g., Phenylephrine)	Could reduce legitimate demand for pseudoephedrine, leading to market contraction for some pharmaceutical applications.	Medium Term
Increased Focus on Novel Precursor Monitoring	Expansion of regulatory scrutiny to other chemicals, creating a more complex landscape for chemical manufacturers.	Medium Term

Key Takeaways

The global supply of pseudoephedrine hydrochloride is characterized by a concentrated manufacturing base, primarily in China, operating under stringent international and national regulatory frameworks designed to prevent diversion to illicit drug production. While legitimate pharmaceutical demand for decongestant formulations remains robust, manufacturers face escalating compliance costs and a dynamic regulatory environment. Emerging trends in tracking technology and the potential development of alternative decongestants suggest a future market shaped by continued efforts to balance public health and safety.

Frequently Asked Questions

1. What is the primary legitimate use of pseudoephedrine hydrochloride? Pseudoephedrine hydrochloride is primarily used as an active pharmaceutical ingredient (API) in over-the-counter and prescription medications for the temporary relief of nasal congestion due to the common cold, hay fever, or other upper respiratory allergies.

2. How do regulations impact the price of pseudoephedrine hydrochloride? Strict regulations increase the cost of doing business for manufacturers and distributors. These include costs for security, detailed record-keeping, reporting suspicious transactions, and obtaining necessary licenses. These compliance costs are often factored into the final price of the API.

3. Are there any significant risks associated with the current supply chain for pseudoephedrine hydrochloride? The primary risk is the diversion of pseudoephedrine hydrochloride or its precursors for the illicit manufacture of methamphetamine. This risk necessitates constant vigilance and robust control measures by both manufacturers and regulatory authorities.

4. What is the role of the International Narcotics Control Board (INCB) in the pseudoephedrine supply chain? The INCB monitors the legitimate international trade of pseudoephedrine to prevent its diversion. It facilitates the implementation of international drug control treaties and works with governments to ensure that trade in these substances is conducted in a manner that protects public health while preventing illicit use.

5. Why has phenylephrine emerged as an alternative to pseudoephedrine in some markets? Phenylephrine has gained traction as an alternative, particularly in the U.S. over-the-counter market, due to the stricter retail dispensing regulations imposed on pseudoephedrine by legislation like the Combat Methamphetamine Epidemic Act (CMEA). These regulations make pseudoephedrine less accessible for direct consumer purchase.

Citations

[1] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Company Profile. Retrieved from [Manufacturer's Official Website/Industry Databases - Specific URL would be cited if publicly accessible and stable]

[2] Shandong Xinhua Pharmaceutical Co., Ltd. (n.d.). Product Portfolio. Retrieved from [Manufacturer's Official Website/Industry Databases - Specific URL would be cited if publicly accessible and stable]

[3] Amneal Pharmaceuticals. (n.d.). Product Information. Retrieved from [Company Website/Press Releases - Specific URL would be cited if publicly accessible and stable]

[4] United Nations Office on Drugs and Crime. (1988). United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Retrieved from [UNODC Official Website]

[5] International Narcotics Control Board. (n.d.). Precursors. Retrieved from [INCB Official Website]

[6] U.S. Food and Drug Administration. (2006). FDA: Combat Methamphetamine Epidemic Act of 2005. Retrieved from [FDA Official Website]

[7] European Parliament and Council. (2004). Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors. Official Journal of the European Union, L 47/1.